Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0038
Approved drug; senolytic investigational/off-label research
Dasatinib
Senolytic / Tyrosine kinase
Senescent-cell clearance positioning, especially when paired with quercetin
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule TKI
- Primary mechanism
- Src-family/BCR-ABL kinase inhibition; senescent-cell anti-apoptotic pathway disruption
- Primary market use
- Senolytics / oncology
Pharmacology
- Molecular weight (Da)
- 488.01 (free base)
- Oral bioavailability
- Oral; variable (~14-34% reported)
- Half-life
- ~3-5 h
- Route tags
- Route-dependent / verify
- Evidence level
- Human/Clinical
- Clinical status
- Approved drug; senolytic investigational/off-label research
- Value-for-money score
- 5 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Clinically approved oncology drug; D+Q senolytic use remains investigational and risk-limited